vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Below 50 Day Moving Average – What’s Next?

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $37.10 and traded as low as $34.13. vTv Therapeutics shares last traded at $34.85, with a volume of 88,495 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Evercore initiated coverage on vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Roth Mkm began coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Stock Down 13.8%

The business has a 50-day moving average price of $37.10 and a two-hundred day moving average price of $32.97. The company has a market capitalization of $137.31 million, a price-to-earnings ratio of -10.40 and a beta of 0.40.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.51. On average, sell-side analysts anticipate that vTv Therapeutics Inc. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP raised its holdings in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the last quarter. 683 Capital Management LLC acquired a new position in vTv Therapeutics during the 4th quarter valued at about $731,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics during the 4th quarter worth approximately $221,000. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.